Nikolai Velev

  • Citations Per Year
Learn More
BACKGROUND Resistance to tyrosine kinase inhibitor (TKIs) therapy is associated with the development of kinase domain mutations. Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion(More)
Here, we report the first documented case of long-term remission in a patient with refractory acute myeloid leukemia (AML) after graft failure of allogeneic cord blood stem cells, and subsequent remission of AML, along with an expansion of autologous CD8þ cytotoxic T cells. This 67-year-old Caucasian man developed progressive pancytopenias and was referred(More)
  • 1